REGENXBIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.09 USD | -5.52% |
|
-15.40% | -10.36% |
Financials (USD)
| Sales 2024 * | 134M | Sales 2025 * | 218M | Capitalization | 789M |
|---|---|---|---|---|---|
| Net income 2024 * | -211M | Net income 2025 * | -134M | EV / Sales 2024 * | 4.75 x |
| Net cash position 2024 * | 151M | Net cash position 2025 * | 175M | EV / Sales 2025 * | 2.81 x |
| P/E ratio 2024 * |
-3.91
x | P/E ratio 2025 * |
-6.77
x | Employees | 344 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on REGENXBIO Inc.
More recommendations
More press releases
| 1 day | -5.52% | ||
| 1 week | -15.40% | ||
| Current month | -23.64% | ||
| 1 month | -27.94% | ||
| 3 months | +16.85% | ||
| 6 months | +0.69% | ||
| Current year | -10.36% |
1 week
16.05
18.65
1 month
16.0523.14
Current year
11.8328.80
1 year
11.8328.80
3 years
11.8346.46
5 years
11.8355.23
10 years
7.0785.10
| Managers | Title | Age | Since |
|---|---|---|---|
Kenneth Mills
FOU | Founder | 49 | 08-07-15 |
Vit Vasista
DFI | Director of Finance/CFO | 56 | 09-07-31 |
| Chief Tech/Sci/R&D Officer | - | 15-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 21-09-02 |
David Stump
BRD | Director/Board Member | 74 | 15-10-14 |
| Director/Board Member | 71 | 15-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.76% | 16 M€ | -8.26% | ||
| 0.25% | 27 M€ | -7.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 16.09 | -5.52% | 560,427 |
| 24-04-17 | 17.03 | -2.69% | 413,623 |
| 24-04-16 | 17.5 | -2.89% | 295,968 |
| 24-04-15 | 18.02 | -0.39% | 346,015 |
| 24-04-12 | 18.09 | -4.89% | 542,760 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
17.03
USD
Average target price
39.83
USD
Spread / Average Target
+133.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.36% | 835M | |
| -3.30% | 102B | |
| +1.79% | 96.84B | |
| -0.44% | 21.48B | |
| -18.35% | 20.82B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.84% | 13.78B | |
| +0.59% | 13.4B | |
| +20.86% | 11.06B |
- Stock Market
- Equities
- RGNX Stock
